Lung cancer IHC panel

Lung cancer IHC assay panel
Deliver diagnostic confidence with the Roche lung cancer IHC panel

Lung cancer is an aggressive, deadly disease, causing 1.8 million deaths worldwide in 2020.1 Roche Diagnostics offers a robust menu of lung cancer diagnostic tools. Our portfolio of IHC diagnostic assays, IHC staining products, and more, deliver the high sensitivity and specificity you need.


VENTANA prediluted, optimized reagents


Our antibodies are ready-to-use on the fully automated BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. VENTANA prediluted, optimized reagents consistently demonstrate superior performance when compared with concentrated antibodies that require manual dilution and in-house validation.2


Proven portfolio of lung cancer assays


Our proven portfolio of lung cancer assays can assist in the stratification of disease, including non-small cell lung carcinoma (NSCLC), neuroendocrine carcinoma and their various subtypes.3

Featured assays

VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody
  • The first and only pre-optimized, ready-to-use IVD IHC ROS1assay on the market
  • Highly correlated to FISH break-apart status (92.5% OPA)and 93% sensitive and 100% specific compared to FISH5
  • High correlation between pathologists (96.4% OPA)6
p40 (BC28) Mouse Monoclonal Primary Antibody


  • Found to be as or more sensitive than p637
  • Studies indicate p40 has higher specificity in squamous cell carcinoma than p637,8
  • May offer a suitable replacement for p63 in various tumor types7,9,10
  • Can be used in a stratification panel with other key markers3,11,12
immunohistochemical staining with Basal Cell Cocktail 34ßE12 + p63
TTF-1 (SP141) Rabbit Monoclonal Primary Antibody


  • Aids in investigation of metastatic carcinomas of unknown origin13
  • Equal or better lung carcinoid detection than other on-market clones14
  • Commonly used in lung stratification panels with other key markers3,11,12
immunohistochemical staining with Basal Cell Cocktail 34ßE12 + p63
Cytokeratin 5/6 (D5/16B4) Mouse Monoclonal Primary Antibody


  • Aids in the identification of squamous cell carcinoma15
  • Aids in the differentiation of malignant mesothelioma from lung adenocarcinoma16
  • Commonly used in a stratification panel with other markers3,11,12
immunohistochemical staining with Basal Cell Cocktail 34ßE12 + p63
Napsin A (MRQ-60) Mouse Monoclonal Primary Antibody


  • Useful in the identification of primary and metastatic carcinomas of the lung17
  • Highly specific for lung adenocarcinoma11
  • Commonly used in a lung stratification panel with other key markers3,11,12
Screenshot of doc library

Take an in-depth look at our full lung cancer IHC assay panel.

Search our product catalogs and documentation library in eLabDoc.


  1. Globalcan 2020 website. WHO-IARC. All cancer fact sheet. Accessed on February 9, 2021.
  2. Nordiqc lu-ALK assessment run 57 2019.
  3. Yatabe, Y. et al. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology. 2019. Vol. 14 No. 3: 377-407
  4. Huang, R. et al. Correlation of ROS1 Immunohistochemistry with ROS1 Fusion Status Determined by Fluorescence in Situ Hybridization. Arch Pathol Lab Med. 2020; 144:735–741.
  5. Conde, E. et al. Assessment of a New ROS1 Immunohistochemistry clone (SP384) for the identification of ROS1 Rearrangements in Patients with Non-small cell lung carcinoma:  the ROSING Study. Journal of Thoracic Oncology.2019 Vol. 14 No. 12: 2120-2132
  6. Hanlon-Newell, A. et al. MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists. October 2018 Journal of Thoracic Oncology 13(10):S452-S453.
  7. Bishop, Justin A, Julie Teruya-Feldstein, William H Westra, Giuseppe Pelosi, William D Travis and Natasha Rekhtman. p40 (t,.Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology. 2012 Mar; 25(3):405-15.
  8. Lilo, M. et al. Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations. J Am Soc Cytopathol. 2016; 5(3): 123–132.
  9. Tacha, David PhD; Ryan Bremer, PhD; Thomas Haas, DO; Weiman Qi, PhD, MD. An lmmunohistochemical Analysis of a Newly Developed, Mouse Monoclonal p40 [BC28) Antibody in Lung, Bladder, Skin, Breast, Prostate and Head and Neck Cancers. Arch Pathol Lab Med-Vol 138, October 2014.
  10. Sailer et al. Comparison of p40 (DNp63) and p63 expression in prostate tissues - which one is the superior diagnostic marker for basal cells? Histopathology. 2013. 63: 50-56.
  11. Zhao, W., Wang, H., Peng, Y., et al. Np63, CK5/6, TIF-1 and napsin A. a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol. 2014; 7(7): 4247-4253.
  12. Zhang, K., Deng, H., Cagle, P. Utility of lmmunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update. Archives of Pathology & Laboratory Medicine: December 2014, Vol. 138, No. 12, pp. 1611-1628.
  13. Misch, D., Blum, T., Boch, C., et al. Value of thyroid transcription factor (TIF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer. Diagnostic Pathology (2015) 10:21
  14. Prabhakaran, S. et al. A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer. Pathology and Laboratory Medicine International 2019:11 7–15.
  15. Kargi, A., Gurel, D., Tuna, B. The diagnostic value of TIF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl lmmunohistochem Mal Morphol. 2007 Dec; 15(4):415-20.
  16. Ordonez, N. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998 Oct; 22(10):1215-21.
  17. Ye J, Findeis-Hosey JJ, Yang Q, McMahon LA. Yao JL, Li F, Xu H. Combination of napsin A and TIF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl lmmunohistochem Mal Morphol. 2011 Jul;19 (4):313-7.